Zai Lab Q3 2025 Earnings Preview
Source: SeekingAlpha
2025-11-05 14:01:15 ET
More on Zai Lab
- Zai Lab Limited (ZLAB) Discusses Updated Monotherapy Phase I Data for Zoci and Outlines Next Steps in Clinical Development Transcript
- Zai Lab Limited (ZLAB) Discusses Updated Monotherapy Phase I Data for Zoci and Outlines Next Steps in Clinical Development - Slideshow
- Zai Lab Limited (ZLAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
- Amgen dips after trial update for Zai Lab partnered gastric cancer therapy
- Zai Lab reaffirms $560M-$590M 2025 revenue target as VYVGART and pipeline drive growth
Read the full article on Seeking Alpha
For further details see:
Zai Lab Q3 2025 Earnings Preview
Zai Lab Limited
NASDAQ: ZLAB
ZLAB Trading
0.96% G/L:
$17.90 Last:
323,105 Volume:
$18.07 Open:
ZLAB Latest News
March 17, 2026 04:35:00 pm
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
February 26, 2026 07:00:00 am
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
ZLAB Stock Data
$2,174,273,322
105,108,310
0.9%
39
N/A
Biotechnology & Life Sciences
Healthcare
CN
Shanghai
